-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on AtriCure, Raises Price Target to $48

Benzinga·12/16/2025 15:36:56
语音播报
JP Morgan analyst Lilia-Celine Lozada maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $42 to $48.